ARS Pharmaceuticals (SPRY) Long-Term Investments (2021 - 2026)

ARS Pharmaceuticals (SPRY) posted Long-Term Investments of $24.2 million for Q2 2022, down 44.93% sequentially from $44.0 million in Q1 2022.

Analysis

ARS Pharmaceuticals (SPRY) Long-Term Investments (2021 - 2026) Analysis & Trends

ARS Pharmaceuticals has reported Long-Term Investments for 2 years, with the latest figure at $24.2 million in Q2 2022.

Quarterly Long-Term Investments changed N/A year-over-year to $24.2 million in Q2 2022, while the trailing twelve-month figure through Jun 2022 was $24.2 million (changed N/A YoY) and the FY2021 annual result came in at $64.8 million, changed N/A from the prior year.
Long-Term Investments slipped to $24.2 million in Q2 2022 per SPRY's latest filing, from $44.0 million in the prior quarter.
Over five years, Long-Term Investments peaked at $64.8 million in Q4 2021 and troughed at $24.2 million in Q2 2022.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Investments (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn	5.79 Bn
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn	9.83 Bn
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn	-4.00 Mn
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn	1.77 Bn
5	Revolution Medicines	44.33 Bn	44.33 Bn	-	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn	-
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn	22.17 Mn
8	Royalty Pharma	28.45 Bn	27.61 Bn	-	372.10 Mn
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	-
10	ARS Pharmaceuticals	561.12 Mn	417.27 Mn	20.81 Mn	19.05 Mn

Historic Data

Download Data